{"entity":{"id":"nct02744287","kind":"trial","name":"Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of BPX-601 run by Regeneron Pharmaceuticals, terminated.","summary":"Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors is a phase 1 interventional study registered as NCT02744287 by Regeneron Pharmaceuticals, with 52 participants enrolled, started 2016-11-30. Conditions recorded: Metastatic Castration-resistant Prostate Cancer and Metastatic Prostate Cancer. Interventions recorded: BPX-601 and Rimiducid.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02744287","url":"https://clinicaltrials.gov/study/NCT02744287"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["bpx-601"],"companies":["bellicum","regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02744287","phase":"1","setting":"A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Previously Treated Advanced Solid Tumors","sponsor":"Regeneron Pharmaceuticals","enrolled":52,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02744287/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"bpx-601","kind":"drug","name":"BPX-601","route":"/drugs/bpx-601/"}],"company":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}